MICHAEL S PERRY Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for MICHAEL S PERRY.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of MICHAEL S PERRY. MICHAEL S PERRY is Director in AmpliPhi Biosciences Corp ($APHB) and Director in ARROWHEAD PHARMACEUTICALS, INC. ($ARWR) and Chief Executive Officer in Avita Therapeutics, Inc. ($RCEL).
Latest Insider Trading Transactions of MICHAEL S PERRY
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, APHB, ARWR, RCEL
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 16 2020 | RCEL | Avita Therapeutics ... | PERRY MICHAEL S | Chief Executive Off ... | Sell | S | 27.41 | 9,000 | 246,690 | 425,087 | 434.1 K to 425.1 K (-2.07 %) |
| Sep 16 2020 | RCEL | Avita Therapeutics ... | PERRY MICHAEL S | Chief Executive Off ... | Sell | S | 27.23 | 23,769 | 647,230 | 434,087 | 457.9 K to 434.1 K (-5.19 %) |
| Sep 16 2020 | RCEL | Avita Therapeutics ... | PERRY MICHAEL S | Chief Executive Off ... | Sell | S | 26.99 | 15,092 | 407,333 | 457,856 | 472.9 K to 457.9 K (-3.19 %) |
| Sep 16 2020 | RCEL | Avita Therapeutics ... | PERRY MICHAEL S | Chief Executive Off ... | Grant | A | 0.00 | 68,504 | 0 | 472,948 | 404.4 K to 472.9 K (+16.94 %) |
| Sep 11 2020 | RCEL | Avita Therapeutics ... | PERRY MICHAEL S | Chief Executive Off ... | Option Exercise | A | 5.99 | 25,000 | 149,750 | 150,000 | |
| Sep 11 2020 | RCEL | Avita Therapeutics ... | PERRY MICHAEL S | Chief Executive Off ... | Sell | S | 26.02 | 20,000 | 520,400 | 404,444 | 424.4 K to 404.4 K (-4.71 %) |
| Sep 11 2020 | RCEL | Avita Therapeutics ... | PERRY MICHAEL S | Chief Executive Off ... | Sell | S | 26.26 | 7,128 | 187,181 | 424,444 | 431.6 K to 424.4 K (-1.65 %) |
| Sep 11 2020 | RCEL | Avita Therapeutics ... | PERRY MICHAEL S | Chief Executive Off ... | Grant | A | 0.00 | 83,333 | 0 | 431,572 | 348.2 K to 431.6 K (+23.93 %) |
| May 18 2020 | ARWR | ARROWHEAD PHARMACE ... | PERRY MICHAEL S | Director | Option Exercise | M | 4.20 | 25,000 | 105,000 | 0 | |
| May 18 2020 | ARWR | ARROWHEAD PHARMACE ... | PERRY MICHAEL S | Director | Option Exercise | M | 5.19 | 15,000 | 77,850 | 25,000 | |
| May 18 2020 | ARWR | ARROWHEAD PHARMACE ... | PERRY MICHAEL S | Director | Option Exercise | M | 2.62 | 10,000 | 26,200 | 40,000 | |
| May 18 2020 | ARWR | ARROWHEAD PHARMACE ... | PERRY MICHAEL S | Director | Option Exercise | M | 2.19 | 15,000 | 32,850 | 50,000 | |
| May 18 2020 | ARWR | ARROWHEAD PHARMACE ... | PERRY MICHAEL S | Director | Option Exercise | M | 2.01 | 5,000 | 10,050 | 65,000 | |
| May 18 2020 | ARWR | ARROWHEAD PHARMACE ... | PERRY MICHAEL S | Director | Option Exercise | M | 4.75 | 7,000 | 33,250 | 70,000 | |
| May 18 2020 | ARWR | ARROWHEAD PHARMACE ... | PERRY MICHAEL S | Director | Buy | M | 4.20 | 25,000 | 105,000 | 85,000 | 60 K to 85 K (+41.67 %) |
| May 18 2020 | ARWR | ARROWHEAD PHARMACE ... | PERRY MICHAEL S | Director | Buy | M | 5.19 | 15,000 | 77,850 | 60,000 | 45 K to 60 K (+33.33 %) |
| May 18 2020 | ARWR | ARROWHEAD PHARMACE ... | PERRY MICHAEL S | Director | Buy | M | 2.62 | 10,000 | 26,200 | 45,000 | 35 K to 45 K (+28.57 %) |
| May 18 2020 | ARWR | ARROWHEAD PHARMACE ... | PERRY MICHAEL S | Director | Buy | M | 2.19 | 15,000 | 32,850 | 35,000 | 20 K to 35 K (+75.00 %) |
| May 18 2020 | ARWR | ARROWHEAD PHARMACE ... | PERRY MICHAEL S | Director | Buy | M | 2.01 | 5,000 | 10,050 | 20,000 | 15 K to 20 K (+33.33 %) |
| May 18 2020 | ARWR | ARROWHEAD PHARMACE ... | PERRY MICHAEL S | Director | Buy | M | 4.75 | 7,000 | 33,250 | 15,000 | 8 K to 15 K (+87.50 %) |
| May 13 2020 | ARWR | ARROWHEAD PHARMACE ... | PERRY MICHAEL S | Director | Sell | S | 36.42 | 6,100 | 222,162 | 8,000 | 14.1 K to 8 K (-43.26 %) |
| May 13 2020 | ARWR | ARROWHEAD PHARMACE ... | PERRY MICHAEL S | Director | Sell | S | 35.71 | 29,900 | 1,067,729 | 14,100 | 44 K to 14.1 K (-67.95 %) |
| Sep 11 2019 | ARWR | ARROWHEAD PHARMACE ... | PERRY MICHAEL S | Director | Sell | S | 30.00 | 85,000 | 2,550,000 | 36,000 | 121 K to 36 K (-70.25 %) |
| Sep 11 2019 | ARWR | ARROWHEAD PHARMACE ... | PERRY MICHAEL S | Director | Sell | S | 28.90 | 100,000 | 2,890,000 | 121,000 | 221 K to 121 K (-45.25 %) |
| May 24 2019 | APHB | Armata Pharmaceuti ... | PERRY MICHAEL S | Director | Option Exercise | A | 3.15 | 27,383 | 86,256 | 27,383 | |
| Jan 03 2019 | ARWR | ARROWHEAD PHARMACE ... | PERRY MICHAEL S | Director | Grant | A | 0.00 | 36,000 | 0 | 221,000 | 185 K to 221 K (+19.46 %) |
| Mar 26 2018 | APHB | AmpliPhi Bioscienc ... | PERRY MICHAEL S | Director | Buy | P | 1.10 | 181,820 | 200,002 | 411,105 | 229.3 K to 411.1 K (+79.30 %) |
| Mar 26 2018 | APHB | AmpliPhi Bioscienc ... | PERRY MICHAEL S | Director | Buy | P | 0.00 | 105,015 | 0 | 229,285 | 124.3 K to 229.3 K (+84.51 %) |
| Mar 26 2018 | APHB | AmpliPhi Bioscienc ... | PERRY MICHAEL S | Director | Buy | P | 0.00 | 5,757 | 0 | 124,270 | 118.5 K to 124.3 K (+4.86 %) |
| Mar 26 2018 | APHB | AmpliPhi Bioscienc ... | PERRY MICHAEL S | Director | Buy | P | 1.10 | 181,820 | 200,002 | 411,105 | 229.3 K to 411.1 K (+79.30 %) |
| Mar 26 2018 | APHB | AmpliPhi Bioscienc ... | PERRY MICHAEL S | Director | Buy | P | 0.00 | 105,015 | 0 | 229,285 | 124.3 K to 229.3 K (+84.51 %) |
| Mar 26 2018 | APHB | AmpliPhi Bioscienc ... | PERRY MICHAEL S | Director | Buy | P | 0.00 | 5,757 | 0 | 124,270 | 118.5 K to 124.3 K (+4.86 %) |
| Jan 03 2018 | ARWR | ARROWHEAD PHARMACE ... | PERRY MICHAEL S | Director | Grant | A | 0.00 | 30,000 | 0 | 185,000 | 155 K to 185 K (+19.35 %) |
| Sep 12 2017 | APHB | AmpliPhi Bioscienc ... | PERRY MICHAEL S | Director | Option Exercise | A | 0.91 | 10,900 | 9,919 | 10,900 | |
| Jan 04 2017 | ARWR | ARROWHEAD PHARMACE ... | PERRY MICHAEL S | Director | Grant | A | 0.00 | 80,000 | 0 | 155,000 | 75 K to 155 K (+106.67 %) |
| Jan 04 2016 | ARWR | ARROWHEAD PHARMACE ... | PERRY MICHAEL S | Director | Grant | A | 0.00 | 30,000 | 0 | 75,000 | 45 K to 75 K (+66.67 %) |
| Sep 23 2015 | APHB | AmpliPhi Bioscienc ... | PERRY MICHAEL S | Director | Option Exercise | A | 6.38 | 12,800 | 81,664 | 12,800 | |
| Mar 06 2015 | ARWR | ARROWHEAD PHARMACE ... | PERRY MICHAEL S | Director | Grant | A | 0.00 | 30,000 | 0 | 45,000 | 15 K to 45 K (+200.00 %) |
| May 19 2008 | APHB | AmpliPhi Bioscienc ... | PERRY MICHAEL S | Director | Grant | A | 0.00 | 10,000 | 0 | 20,000 | 10 K to 20 K (+100.00 %) |
| May 21 2007 | APHB | AmpliPhi Bioscienc ... | PERRY MICHAEL S | Director | Grant | A | 0.00 | 10,000 | 0 | 10,000 | 0 to 10 K |
| May 10 2006 | APHB | AmpliPhi Bioscienc ... | PERRY MICHAEL S | Director | Option Exercise | A | 0.38 | 20,000 | 7,600 | 20,000 | |
| Nov 02 2005 | APHB | AmpliPhi Bioscienc ... | PERRY MICHAEL S | Director | Option Exercise | A | 0.61 | 60,000 | 36,600 | 60,000 |
Page: 1